Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial

The Lancet Oncology

Volumn 14, Issue 8, 2013, Pages 749-759

  Seymour, Matthew T ^a   Brown, Sarah R ^a   Middleton, Gary ^b   Maughan, Timothy ^c   Richman, Susan ^a   Gwyther, Stephen ^d   Lowe, Catherine ^a   Seligmann, Jennifer F ^a   Wadsley, Jonathan ^e   Maisey, Nick ^f   Chau, Ian ^g   Hill, Mark ^h   Dawson, Lesley ⁱ   Falk, Stephen ^j   O'Callaghan, Ann ^k   Benstead, Kim ^l   Chambers, Philip ^a   Oliver, Alfred ^m   Marshall, Helen ^a   Napp, Vicky ^a   Quirke, Phil ^a   more..

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d EAST SURREY HOSPITAL   (United Kingdom)

^e WESTON PARK HOSPITAL   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h Kent Oncology Centre   (United Kingdom)

ⁱ Edinburgh Cancer Centre   (United Kingdom)

^j BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^k QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^l CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^m NCRN Consumer Liaison Group   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CYCLOSPORIN A; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER PATIENT; CHILL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED KINGDOM; VOMITING;

AGED; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879786289     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70163-3     Document Type: Article

References (34)

1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
2. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.
3. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals Oncol 2011, 22:1535-1546.
4. Middleton GW, Brown SR, Gwyther SJ, et al. Ciclosporin in combination with irinotecan for chemoresistant advanced colorectal cancer: results of PICCOLO, a large randomised trial with prospective molecular stratification. Eur J Cancer 2011, 47:S420-S421.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
6. Weiner LM, Belldegrun AS, Crawford J, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008, 14:502-508.
7. European Organisation for Research and Treatment of Cancer quality of life core questionnaire (accessed May 6, 2013). http://groups.eortc.be/qol/eortc-qlq-c30.
8. Kind P The EuroQoL instrument: an index of health-related quality of life. Quality of life in pharmacoeconomics in clinical trials 1996, Lippincott-Raven, Philadelphia. 2nd edn. B. Spiker (Ed.).
9. Finlay AY, Khan GK Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19:210-216.
10. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009, 27:5931-5937.
11. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418.
12. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: introduction and design. Br J Cancer 1976, 34:585-612.
13. Seymour MT, Brown SR, Richman S, et al. Panitumumab in combination with irinotecan for chemoresistant advanced colorectal cancer: Results of PICCOLO, a large randomised trial with prospective molecular stratification. Eur J Cancer 2011, 47:S393.
14. King MT The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996, 5:555-567.
15. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
16. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
17. Adelstein BA, Dobbins TA, Harris CA, et al. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer 2011, 47:1343-1354.
18. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705.
19. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. NEJM 2009, 360:563-572.
20. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009, 27:5068-5074.
21. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27:5924-5930.
22. Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010, 46:1997-2009.
23. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2311-2319.
24. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:4706-4713.
25. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114.
26. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012, 30:1755-1762.
27. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. NEJM 2008, 359:1757-1765.
28. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680.
29. Borner M, Koeberle D, Von Moos R, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008, 19:1288-1292.
30. Vale CL, Tierney JF, Fisher D, et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 2012, 38:618-625.
31. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012, 307:1383-1393.
32. Taieb J, Tabernero J, Mini E, et al. Adjuvant FOLFOX4 +/- cetuximab in KRAS wild type patients with resected stage III colon cancer. Results from the PETACC8 Intergroup trial. Ann Oncol 2012, 23(suppl 4):iv17. abstr O-0028.
33. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013, 14:29-37.
34. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012, 30:3499-3506.